#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteogenesis imperfecta Familial amyotrophic lateral sclerosis Autoimmune myositis Metastases to peritoneum Osteomyelitis Methylmalonic acidaemia Palmoplantar pustulosis Lymphangioma Cystic fibrosis gastrointestinal disease Depression Mitochondrial DNA depletion Diffuse large B-cell lymphoma refractory Granulomatosis with polyangiitis Hyperinsulinism Cognitive disorder More trials…

    Learn about Rare Diseases

    Alveolar rhabdomyosarcoma Wolfram syndrome Ehlers-Danlos syndrome – Diagnostics Usher’s syndrome – Treatment Mast cell activation syndrome – Life with Disease Cystic fibrosis – Diagnostics Indolent systemic mastocytosis Rhabdomyosarcoma recurrent – Treatment Congenital nephrogenic diabetes insipidus – Life with Disease Pleomorphic leiomyosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ceftazidime Pentahydrate Taldefgrobep Alfa Epinephrine Fipaxalparant Lorundrostat Solrikitug Tanimilast Tub-040 SAR443820 Tiragolumab Vanzacaftor Fusidic Acid Varegacestat Epirubicin Pivekimab Sunirine Filgotinib Polatuzumab Vedotin Savolitinib ALKYLATING AGENTS Evolocumab More therapies…

    Learn about Your Condition

    Pancreatitis chronic Tonsillitis Traumatic pain Primary hypercholesterolaemia Anal cancer stage III Methylmalonic acidaemia Choroid melanoma Psychological trauma Graves' disease Muscle injury Andersen-Tawil syndrome Acoustic neuroma Skin disorder Sickle cell disease Corneal dystrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. KBC Zagreb

KBC Zagreb

Ulica Mije Kispatica 12, Zagreb, 10000, Croatia

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Acasunlimab
    • Anakinra
    • Betamethasone Sodium Phosphate
    Austria Belgium Bulgaria Croatia Estonia France +9

  • Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Quizartinib Dihydrochloride
    • Idarubicin Hydrochloride
    • Daunorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Eftilagimod Alfa
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Croatia Germany Greece +9

  • Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Nivolumab
    Croatia Czechia Estonia France Germany Hungary +6

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Drugs:
    • Tolebrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis relapse
    Investigated Drugs:
    • A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)
    • A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 Cvr-167)
    • B/Austria/1359417/2021-Like Strain (B/Singapore/Wuh4618/2021)
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Study on Fenebrutinib for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Croatia Czechia Slovakia

  • Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Epcoritamab
    • Gemcitabine
    • Lenalidomide
    Belgium Bulgaria Croatia Czechia France Greece +5

  • Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tanimilast
    • Roflumilast
    Austria Bulgaria Croatia Czechia Estonia Germany +8

  • Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Coagulopathy
    Investigated Drugs:
    • Human Coagulation Factor Ii
    • Human Coagulation Factor Ix
    • Human Coagulation Factor Vii
    Austria Croatia Germany Italy Poland Spain
Previous Page
1 … 7 8 9 10 11 … 16
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!